Christopher A. Klebanoff, MD, discusses using biosimilars to reduce financial toxicity in breast cancer.
Christopher A. Klebanoff, MD
Advertisement
Articles by Christopher A. Klebanoff, MD
Advertisement
Latest Updated Articles
Dr. Klebanoff on Biosimilars Reducing Financial Toxicity in Breast CancerPublished: December 19th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5